We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more
LF7.5
Lactoferrin Research
Mostly mechanism / observationalLimited safety
21 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Lactoferrin studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from high-quality meta-analyses and randomised trials published 2009–2026 with a typical study size of 120 participants.
Based on 21 studies · 8 meta-analyses · 6 RCTs · 754 total participants
Confidence
High
What the studies found
1helped· 20 more without graded effect data
By outcome
Safety profile
Mostly mechanism / observational9 studies
Immune supportReduced frequency and duration of respiratory and GI infections · 4–8 weeks
Mostly mechanism / observational6 studies
InflammationMeasurable reductions in IL-6 and systemic inflammatory markers · 4–8 weeks
Mostly mechanism / observational3 studies
Women's healthReduced iron-deficiency anemia in pregnancy with fewer GI side effects than ferrous sulfate · 4–8 weeks
Mostly mechanism / observational3 studies
Therapeutic & clinical
Mostly mechanism / observational3 studies
Iron status & anemia
Too few graded studies2 studies
Digestive healthImproved gut barrier integrity and reduced intestinal permeability · 4–12 weeks
14 studies in the last 5 years · Latest meta-analysis: 2023
200920172026
1Systematic Review2026
Further studies are needed to determine optimal administration routes and dosages for clinical applications.
Nakamura A et al. · Reproductive sciences (Thousand Oaks, Calif.) (2026)
Furthermore, an in vitro study demonstrated that LF selectively induced cell cycle arrest in endometriotic stromal cells without affecting that of eutopic endometrial cells.
Compared with other non-hormonal therapies, LF has an extremely lower risk of teratogenicity and fetal toxicity and could improve reproductive outcomes and perinatal prognosis, indicating its potential for continuous administration throughout various life stages.
Further studies are needed to determine optimal administration routes and dosages for clinical applications.
By addressing both established and underexplored applications, this review provides a translational framework for clinical development and provides a comprehensive rationale behind leveraging lactoferrin for hair and skin epithelial health.
Kaplan N et al. · International journal of molecular sciences (2026)
We link mechanistic insights with clinical and preclinical evidence and uniquely map molecular functions to dermatologic and trichologic outcomes.
In summary, we propose lactoferrin as not just an anti-inflammatory molecule, but also as a microenvironment stabilizer, and particularly relevant for hair and skin support as an alternative to pharmacological interventions.
By addressing both established and underexplored applications, this review provides a translational framework for clinical development and provides a comprehensive rationale behind leveraging lactoferrin for hair and skin epithelial health.
Therefore, future research should focus on molecular structures, target sites, and dose-response relationships, alongside well-designed clinical trials to validate efficacy and support diabetes prevention and management.
Chen W et al. · Journal of agricultural and food chemistry (2026)
In this review, we classified the milk-derived bioactive components by their biochemical nature and listed their hypoglycemic mechanisms.
Among these components, milk-derived peptides (e.g., casein hydrolysates), lactoferrin, microRNA, and mineral elements are considered key contributors to the hypoglycemic properties.
Challenges remain in current research, particularly regarding the dose-dependent effects, population variability, processing impacts, and allergenic risks.
This systematic-review examined the effects of Lactoferrin.
Tang T et al. · Biomolecules (2026)
Concurrently, the activity of endogenous antioxidant enzymes (such as superoxide dismutase and glutathione peroxidase) decreases, and the levels of tear antioxidants such as lactoferrin also decrease.
These age-related changes collectively lead to excessive accumulation of ROS, triggering oxidative stress that directly damages biomacromolecules in ocular surface cells and impairs the stability of the tear film.
Furthermore, we have summarized the current therapeutic strategies for oxidative stress in DED, including both conventional antioxidants and emerging approaches such as eye drops based on nanoenzymes, thermosensitive hydrogels, intense pulsed light therapy, and drug-eluting contact lenses.
By bridging biological insights with clinical realities, this review offers a roadmap for developing next-generation, disease-modifying therapies for DED.
Yang C et al. · Experimental eye research (2026)
The barriers to clinical translation are addressed, advocating for a paradigm shift towards biomarker-driven precision medicine and the development of advanced ocular drug delivery systems.
By bridging biological insights with clinical realities, this review offers a roadmap for developing next-generation, disease-modifying therapies for DED.
Oral lactoferrin supplementation is as effective as ferrous sulfate in treating iron-deficiency anemia with a more favorable gastrointestinal side-effect profile.
Zhao X et al. · Nutrients (2022)
Lactoferrin was non-inferior to ferrous sulfate for increasing hemoglobin and serum ferritin
Gastrointestinal adverse effects were significantly lower with lactoferrin than ferrous sulfate
Lactoferrin improved iron status in pregnant women, children, and adults with IDA
11Vulvovaginal candidiasis recurrenceRCTCited 56×n=109 · medium study2019
Combination of oral probiotics and lactoferrin significantly reduced recurrence of vulvovaginal candidiasis compared to placebo in a 6-month maintenance protocol.
Russo R et al. · Mycoses (2019)
Recurrence rate of vulvovaginal candidiasis was significantly lower in the probiotic + lactoferrin group vs placebo
Time to first recurrence was significantly prolonged in the active treatment group
Symptom severity scores were lower in women receiving the combination treatment
Bovine lactoferrin at doses of 200 mg and 600 mg daily was safe and well-tolerated in healthy adults with measurable immunomodulatory effects at higher doses.
Peterson RD et al. · International Journal of Toxicology (2025)
Both 200 mg and 600 mg/day lactoferrin were safe with no significant adverse events in healthy adults
600 mg/day produced greater modulation of NK cell activity and cytokine profiles than 200 mg/day
No clinically significant changes in liver or kidney function markers were observed
Bovine lactoferrin supplementation did not significantly reduce COVID-19 infection rates in healthcare personnel compared to placebo in this double-blind RCT.
Navarro R et al. · Biometals (2023)
No significant difference in COVID-19 infection incidence between lactoferrin and placebo groups in healthcare workers
Secondary outcomes including symptom severity showed a trend toward improvement with lactoferrin
Lactoferrin was safe and well-tolerated throughout the trial period
A multi-ingredient supplement containing lactoferrin significantly improved muscle mass, gut permeability markers, and inflammatory indices in older adults with sarcopenia.
Rondanelli M et al. · Nutrients (2024)
Combination supplement containing lactoferrin improved appendicular skeletal muscle mass index in sarcopenic elderly
Intestinal permeability markers (zonulin, LPS) were significantly reduced in the treatment group
Inflammatory markers including IL-6 and CRP were reduced with the lactoferrin-containing formulation